Novo Nordisk (NVO) Stock
Fundamentals
Source: third-party data provider, as of October 15, 2026
Compare with NVO
Recent news

UnitedHealth Stock News (Oct 14, 2026): UNH Falls 0.2% to $377.76
UnitedHealth Stock News (Oct 14, 2026): UNH Falls 0.2% to $377.76
NVO

Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
NVO

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
NVO

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 35.60
- MACD 12/26/9
- -1.46
- EMA 9 of MACD
- -1.74
- MACD histogram
- 0.28
- SMA 50
- $42.96
- Price below SMA 50
- EMA 50
- $41.89
- Price below EMA 50
- SMA 200
- $45.19
- Price below SMA 200
- EMA 200
- $45.14
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Sell
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.78 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

UnitedHealth Stock News (Oct 14, 2026): UNH Falls 0.2% to $377.76
UnitedHealth Stock News (Oct 14, 2026): UNH Falls 0.2% to $377.76
NVO

Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
NVO

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
NVO

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
NVO

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
NVO

Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
NVO

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
NVO

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
NVO

Eli Lilly’s Push Beyond Weight Loss Gets Another Boost – FDA Grants Cancer Drug Orphan Drug Status
Eli Lilly’s Push Beyond Weight Loss Gets Another Boost – FDA Grants Cancer Drug Orphan Drug Status
NVO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Maziar Mike Doustdar B.A. | President, CEO & Member of the Management Board | 1970 |
| Ms. Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board | 1986 |
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board | 1971 |
| Dr. Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board | 1970 |
| Ms. Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board | 1977 |
| Ms. Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board | 1982 |
| Mr. John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board | 1972 |
| Mr. Emil Kongshoej Larsen | EVP of International Operations & Member of Management Board | 1975 |
| Mr. Jamey Millar | Executive VP of US Operations & Member of Management Board | 1968 |
| Ms. Hong Chow | Executive VP of Product & Portfolio Strategy and Member of Management Board | 1971 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 15, 2026
Technical indicators
- RSI 14
- 35.60
- MACD 12/26/9
- -1.46
- EMA 9 of MACD
- -1.74
- MACD histogram
- 0.28
- SMA 50
- $42.96
- Price below SMA 50
- EMA 50
- $41.89
- Price below EMA 50
- SMA 200
- $45.19
- Price below SMA 200
- EMA 200
- $45.14
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $40.00
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +6.5 | -2.4 | +4.4 | |||||||||
| 2022 | -8.2 | +0.4 | +7.2 | +1.0 | -3.0 | +1.0 | +4.0 | -8.6 | -4.7 | +6.1 | +17.1 | +7.3 |
| 2023 | +1.3 | +1.4 | +11.4 | +4.7 | -4.2 | +2.4 | +1.0 | +14.8 | -3.9 | +5.2 | +4.3 | +3.0 |
| 2024 | +12.4 | +3.4 | +3.4 | +0.6 | +4.7 | +5.2 | -8.8 | +5.1 | -12.6 | -5.1 | -4.6 | -20.8 |
| 2025 | -3.5 | +9.7 | -22.3 | -2.3 | +9.0 | -5.2 | -32.6 | +17.2 | -1.6 | -16.4 | +0.5 | +5.1 |
| 2026 | +13.4 | -36.5 | -2.7 | +15.7 | +3.9 | +8.8 | -3.5 | -3.7 | -16.0 | +1.9 |
Corporate actions
Upcoming
No upcoming corporate actions for NVO



